Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Needham Ups Encysive Pharmaceuticals to 'Buy'


Needham upgraded Encysive Pharmaceuticals (ENCY) to buy from hold.

Analyst Mark Monane says he favors a newly formed plan for the company going forward, including its focus on sitaxsentan, the recent reacquisition of rights for sitaxsentan from ICOS Pharmaceuticals, FDA issuance of Special Protocol Assessment for the STRIDE II trial, and the firm's leadership under Bruce Given.

He believes the current valuation doesn't reflect the market potential of sitaxsentan, Encysive's lead drug candidate for pulmonary arterial hypertension. If the current trial is successful, Monane says he expects sitaxsentan to hit the marketplace in early 2006, and generate peak sales of $300 million to $400 million. He set a $9 target.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus